Loading clinical trials...
Loading clinical trials...
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Conditions
Interventions
LY3372689
LY3372689
+1 more
Locations
69
United States
Hope Clinical Research, Inc.
Canoga Park, California, United States
Neuro-Pain Medical Center
Fresno, California, United States
Irvine Clinical Research
Irvine, California, United States
Sharp Mesa Vista Hospital
San Diego, California, United States
Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States
JEM Research Institute
Atlantis, Florida, United States
Start Date
September 16, 2021
Primary Completion Date
July 9, 2024
Completion Date
May 22, 2025
Last Updated
July 28, 2025
NCT07545473
NCT04570085
NCT07531732
NCT07290387
NCT06501495
NCT06121544
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions